Cargando…

Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States

BACKGROUND: Immune-related adverse events (irAEs) are a common phenomenon in cancer patients treated with immune checkpoint inhibitors (ICIs). Surprisingly, the toxicity burdens of these irAEs have not been illustrated clearly. In this study, we analyzed irAEs for seven FDA-approved ICIs in cancer t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Fan, Shay, Chloe, Abousaud, Marin, Tang, Chris, Li, Yamin, Qin, Zhaohui, Saba, Nabil F., Teng, Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9814433/ https://www.ncbi.nlm.nih.gov/pubmed/36600271 http://dx.doi.org/10.1186/s13046-022-02568-y

Ejemplares similares

Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics
por: Twomey, Julianne D., et al.
Publicado: (2021)

A Comprehensive Review of US FDA-Approved Immune Checkpoint Inhibitors in Urothelial Carcinoma
por: Hsu, Fu-Shun, et al.
Publicado: (2017)

Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence
por: Vaddepally, Raju K., et al.
Publicado: (2020)

FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients
por: Wang, Ye, et al.
Publicado: (2021)

Publication statuses of clinical trials supporting FDA-approved immune checkpoint inhibitors: a meta-epidemiological investigation
por: Omae, Kenji, et al.
Publicado: (2019)

Prescription Drugs Marketed in the United States Should Be Approved by the FDA
por: Shepherd, Marvin
Publicado: (2003)

FDA Approvals of Biologics in 2022
por: Martins, Alexander C., et al.
Publicado: (2023)

Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices
por: Van Norman, Gail A.
Publicado: (2016)

Inhibition of HEV Replication by FDA-Approved RdRp Inhibitors
por: Hooda, Preeti, et al.
Publicado: (2023)

Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
por: Wu, Qing, et al.
Publicado: (2022)

The quality of reporting general safety parameters and immune-related adverse events in clinical trials of FDA-approved immune checkpoint inhibitors
por: Karimian, Zahra, et al.
Publicado: (2020)

Why Did the FDA Approve These Advertisements?
por: Oaks, David
Publicado: (2006)

FDA approved ready to use phenylephrine
por: Bhatia, Pradeep Kumar, et al.
Publicado: (2021)

An insider's perspective on FDA approval of aducanumab
por: Wang, Yaning
Publicado: (2023)

Alchemical analysis of FDA approved drugs
por: Orsi, Markus, et al.
Publicado: (2023)

Screening of FDA-Approved Drugs for Inhibitors of Japanese Encephalitis Virus Infection
por: Wang, Shaobo, et al.
Publicado: (2017)

FDA-Approved Kinase Inhibitors in Preclinical and Clinical Trials for Neurological Disorders
por: Lui, Austin, et al.
Publicado: (2022)

Discovery and Characterization of Synthesized and FDA-Approved Inhibitors of Clostridial and Bacillary Collagenases
por: Alhayek, Alaa, et al.
Publicado: (2022)

A Systematic Screen of FDA-Approved Drugs for Inhibitors of Biological Threat Agents
por: Madrid, Peter B., et al.
Publicado: (2013)

Repurposing FDA-approved sulphonamide carbonic anhydrase inhibitors for treatment of Neisseria gonorrhoeae
por: Abutaleb, Nader S., et al.
Publicado: (2021)

FDA approved drugs as potential Ebola treatments
por: Ekins, Sean, et al.
Publicado: (2015)

FDA-approved medications that impair human spermatogenesis
por: Ding, Jiayi, et al.
Publicado: (2016)

FDA approved antibacterial drugs: 2018-2019
por: Andrei, Stefan, et al.
Publicado: (2019)

The current landscape of the FDA approved companion diagnostics
por: Jørgensen, Jan Trøst
Publicado: (2021)

FDA-Approved Oximes and Their Significance in Medicinal Chemistry
por: Dhuguru, Jyothi, et al.
Publicado: (2022)

Timeline of FDA-Approved Targeted Therapy for Cholangiocarcinoma
por: Cho, Su Min, et al.
Publicado: (2022)

FDA approved vaccines for monkeypox: Current eminence
por: Chopra, Hitesh, et al.
Publicado: (2022)

Screening and Identification of Lassa Virus Entry Inhibitors from an FDA-Approved Drug Library
por: Wang, Peilin, et al.
Publicado: (2018)

Identification of new EphA4 inhibitors by virtual screening of FDA-approved drugs
por: Gu, Shuo, et al.
Publicado: (2018)

Proteasomal adaptations to FDA-approved proteasome inhibitors: a potential mechanism for drug resistance?
por: Kim, Kyung Bo
Publicado: (2021)

Repurposing FDA-approved drugs as inhibitors of therapy-induced invadopodia activity in glioblastoma cells
por: Jones, Dylan, et al.
Publicado: (2022)

The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors
por: Davis, Andrew A., et al.
Publicado: (2019)

Quantitative analysis on the characteristics of targets with FDA approved drugs
por: Sakharkar, Meena K., et al.
Publicado: (2007)

FDA-Approved Natural Polymers for Fast Dissolving Tablets
por: Alam, Md Tausif, et al.
Publicado: (2014)

Repurposing FDA-approved drugs for anti-aging therapies
por: Snell, Terry W., et al.
Publicado: (2016)

A systematic analysis of FDA-approved anticancer drugs
por: Sun, Jingchun, et al.
Publicado: (2017)

First vaccine approval under the FDA Animal Rule
por: Beasley, David W C, et al.
Publicado: (2016)

A Comprehensive Map of FDA-Approved Pharmaceutical Products
por: Zhong, Hao, et al.
Publicado: (2018)

THPdb: Database of FDA-approved peptide and protein therapeutics
por: Usmani, Salman Sadullah, et al.
Publicado: (2017)

New FDA approved antibacterial drugs: 2015-2017
por: Andrei, Stefan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_adhvr8p7lmnejpk68mlk73rbuu